{"id":58543,"date":"2026-05-01T05:37:23","date_gmt":"2026-05-01T05:37:23","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/58543\/"},"modified":"2026-05-01T05:37:23","modified_gmt":"2026-05-01T05:37:23","slug":"swiss-pharma-firm-novartis-plans-seventh-us-plant-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/58543\/","title":{"rendered":"Swiss pharma firm Novartis plans seventh US plant"},"content":{"rendered":"

\"Novartis<\/p>\n

Novartis opens seventh plant in the United States <\/p>\n

Keystone-SDA <\/p>\n

Novartis is expanding its production capacity in the United States, with the announcement of a new site in Morrisville, North Carolina. This plant is the seventh site as part of the Swiss pharma’s $23 billion (CHF18 million) investment plan in the US.\n<\/p>\n

Listen to the article <\/p>\n

Listening the article <\/p>\n

Toggle language selector <\/p>\n

English (US) <\/p>\n

English (British) <\/p>\n

Generated with artificial intelligence. <\/p>\n

This content was published on <\/p>\n

April 30, 2026 – 16:15\n<\/p>\n

+ Get the most important news from Switzerland in your inbox<\/a><\/p>\n

The new plant will be dedicated to the production of active pharmaceutical ingredients for solid formulations (tablets, capsules) as well as for RNA-based therapies, the Basel-based pharmaceutical group said in a press release on Thursday.<\/p>\n

The 56,200-square-foot facility will bring the company\u2019s North Carolina presence to five sites in three locations.<\/p>\n

End-to-end integrated production<\/p>\n

Since committing in April 2025 to produce all of its key medicines for US patients in the US, Novartis has made significant progress in its plans to establish end-to-end integrated manufacturing.<\/p>\n

In November 2025, a dedicated manufacturing facility for radioligand therapy was opened in Carlsbad, California. It serves the western US, Alaska and Hawaii.<\/p>\n

In December 2025, construction began on a flagship industrial site in North Carolina. It includes the production and packaging of tablets, capsules and biologics for treatments covering oncology, immunology, neuroscience, cardiovascular, renal and metabolic diseases.<\/p>\n

\n More<\/p>\n

\"Roche<\/p>\n

More <\/p>\n

Healthcare innovation\n <\/p>\n

US trade deal forces reckoning for Swiss pharma powerhouse <\/p>\n

\n

This content was published on <\/p>\n

Nov 18, 2025 <\/p>\n

Swiss pharma made massive investment promises to the US that are fueling anxiety about the industry\u2019s future in Switzerland. <\/p>\n

<\/p>\n

Read more: US trade deal forces reckoning for Swiss pharma powerhouse
\n <\/a><\/p>\n

In January 2026, Novartis announced a new manufacturing site dedicated to radioligand therapies in Winter Park, Florida, the first in the southeastern US. Construction of a new biomedical research centre in San Diego, California, began in February 2026. Also that month, a new production site in Denton, Texas, dedicated to radioligand therapies for cancer patients, was announced.<\/p>\n

Finally, expansion of the existing sites in Indianapolis, Indiana, and Millburn, New Jersey, is currently under way.<\/p>\n

Translated from German by AI\/jdp<\/p>\n

How we work <\/p>\n

We select the most relevant news for an international audience and use automatic translation tools to translate them into English. A journalist then reviews the translation for clarity and accuracy before publication.\u00a0\u00a0<\/p>\n

Providing you with automatically translated news gives us the time to write more in-depth articles. The news stories we select have been written and carefully fact-checked by an external editorial team from news agencies such as Bloomberg or Keystone.<\/p>\n

If you have any questions about how we work, write to us at\u00a0english@swissinfo.ch<\/a>.<\/p>\n

Articles in this story <\/p>\n","protected":false},"excerpt":{"rendered":"Novartis opens seventh plant in the United States Keystone-SDA Novartis is expanding its production capacity in the United…\n","protected":false},"author":2,"featured_media":58295,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[127],"tags":[101,595,300,114,1002,100,566,206,103,102],"class_list":{"0":"post-58543","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novartis","8":"tag-article","9":"tag-beat-new-treatments","10":"tag-beat-pharma-supply-chains","11":"tag-business","12":"tag-health","13":"tag-latest-news","14":"tag-multinationals","15":"tag-novartis","16":"tag-production-type-deepl-autotranslation","17":"tag-sda-ready-to-publish"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116497707480891476","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/58543","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=58543"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/58543\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/58295"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=58543"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=58543"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=58543"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}